CD8A and cancer: In agreement with these reports, IL-10 can stimulate NK cell and alloreactive CD8+ T cell responses in vitro and in vivo and may have the same effect in certain cancers or subsets of patients (Groux et al., 1998, 1999; Cai et al., 1999; Micallef et al., 1999; Lauw et al., 2000).